Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys

Experimental Neurology

Volumn 182, Issue 2, 2003, Pages 490-496

  Chassain, C ^a   Eschalier, A ^a   Durif, F ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); Antiparkinsonian effect; Levodopa induced dyskinesia; Magnesium sulfate; Monkeys; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; LEVODOPA; MAGNESIUM SULFATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG EFFECT; DYSKINESIA; FEMALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RHESUS MONKEY;

EID: 0042200743     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(03)00125-0     Document Type: Article

References (45)

1. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits neural substrates of parallel processing . Trends Neurosci. 13:(7):1990;266-271.
2. Begon S., Pickering G., Eschalier A., Dubray C. Magnesium increases morphine analgesic effect in different experimental models of pain. Anesthesiology. 96:(3):2002;627-632.
3. Bergman H., Wichmann T., DeLong M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 249:(4975):1990;1436-1438.
4. Blanchet P.J., Konitsiotis S., Chase T.N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. 13:(5):1998;798-802.
5. Blanchet P.J., Konitsiotis S., Whittemore E.R., Zhou Z.L., Woodward R.M., Chase T.N. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 290:(3):1999;1034-1040.
6. Blanchet P.J., Papa S.M., Metman L.V., Mouradian M.M., Chase T.N. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci. Biobehav. Rev. 21:(4):1997;447-453.
7. Calabresi P., Mercuri N.B., Sancesario G., Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain. 116:1993;433-452.
8. Calon F., Morissette M., Ghribi O., Goulet M., Grondin R., Blanchet P.J., Bedard P.J., Di P.T. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry. 26:(1):2002;127-138.
9. Chase T.N., Oh J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23:(Suppl 10):2000;S86-91.
10. Chase T.N., Oh J.D., Blanchet P.J. Neostriatal mechanisms in Parkinson's disease. Neurology. 51:(Suppl 2):1998;S30-35.
11. Chassain C., Eschalier A., Durif F. Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP. J. Neurosci. Methods. 111:(1):2001;9-16.
12. Davies J., Watkins J.C. Effect of magnesium ions on the responses of spinal neurones to excitatory amino acids and acetylcholine. Brain Res. 130:(2):1977;364-368.
13. Decollogne S., Tomas A., Lecerf C., Adamowicz E., Seman M. NMDA receptor complex blockade by oral administration of magnesium comparison with MK-801 . Pharmacol. Biochem. Behav. 58:(1):1997;261-268.
14. Engber T.M., Papa S.M., Boldry R.C., Chase T.N. NMDA receptor blockade, reverses motor response alterations induced by levodopa. NeuroReport. 5:(18):1994;2586-2588.
15. Gomez-Mancilla B., Boucher R., Gagnon C., Di Paolo T., Markstein R., Bedard P.J. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors . Mov. Disord. 8:(2):1993;144-150.
16. Gotz T., Kraushaar U., Geiger J., Lubke J., Berger T., Jonas P. Functional properties of AMPA and NMDA receptors expressed in identified types of basal ganglia neurons. J. Neurosci. 17:(1):1997;204-215.
17. Greenamyre J.T. Glutamate-dopamine interactions in the basal ganglia relationship to Parkinson's disease . J. Neural Transm. Gen. Sect. 91:(2-3):1993;255-269.
18. Greenamyre J.T., Eller R.V., Zhang Z., Ovadia A., Kurlan R., Gash D.M. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol. 35:(6):1994;655-661.
19. Greenamyre J.T., O'Brien C.F. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol. 48:(9):1991;977-981.
20. Hollmann M., Heinemann S. Cloned glutamate receptors. Annu. Rev. Neurosci. 17:1994;31-108.
21. Klockgether T., Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann. Neurol. 28:(4):1990;539-546.
22. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 54:(8):2000;1589-1595.
23. Liu H.T., Hollmann M.W., Liu W.H., Hoenemann C.W., Durieux M.E. Modulation of NMDA receptor function by ketamine and magnesium Part I . Anesth. Analg. 92:(5):2001;1173-1181.
24. Marsden C.D. Problems with long-term levodopa therapy for Parkinson's disease. Clin. Neuropharmacol. 17:(Suppl 2):1994;S32-44.
25. Mitchell I.J., Carroll C.B. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission potential mechanisms of action . Neurosci. Biobehav. Rev. 21:(4):1997;469-475.
26. Morgenroth V.H., Hegstrand L.R., Roth R.H., Greengard P. Evidence for involvement of protein kinase in the activation by adenosine 3′:5′-monophosphate of brain tyrosine 3-monooxygenase. J. Biol. Chem. 250:(5):1975;1946-1948.
27. Mori H., Masaki H., Yamakura T., Mishina M. Identification by mutagenesis of a Mg(2+)-block site of the NMDA receptor channel. Nature. 358:(6388):1992;673-675.
28. Mori H., Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology. 34:(10):1995;1219-1237.
29. Morris M.E. Brain and CSF magnesium concentrations during magnesium deficit in animals and humans neurological symptoms . Magnes. Res. 5:(4):1992;303-313.
30. Nash, J.E., S.H. Fox, B. Henry, M.P. Hill, D. Peggs, S. McGuire, Y. Maneuf C. Hille, J.M. Brotchie, A.R. 2000. Crossman. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 165(1), 136-142, doi:10.1006/exnr.2000.7444.
31. Nash J.E., Hill M.P., Brotchie J.M. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp. Neurol. 155:(1):1999;42-48 doi:10.1006/exnr.1998.6963.
32. Oh J.D., Russell D.S., Vaughan C.L., Chase T.N., Russell D. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits effect of dopaminergic denervation and L-Dopa administration . Brain Res. 813:(1):1998;150-159.
33. Oh J.D., Vaughan C.L., Chase T.N. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res. 821:(2):1999;433-442.
34. Papa S.M., Boldry R.C., Engber T.M., Kask A.M., Chase T.N. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 701:(1-2):1995;13-18.
35. Papa S.M., Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39:(5):1996;574-578.
36. Parsons C.G. NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol. 429:(1-3):2001;71-78.
37. Rascol O., Sabatini U., Brefel C., Fabre N., Rai S., Senard J.M., Celsis P., Viallard G., Montastruc J.L., Chollet F. Cortical motor overactivation in parkinsonian patients with L-Dopa-induced peak-dose dyskinesia. Brain. 121:1998;527-533.
38. Robertson R.G., Farmery S.M., Sambrook M.A., Crossman A.R. Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Res. 476:(2):1989;317-322.
39. Scherman D., Desnos C., Darchen F., Pollak P., Javoy-Agid F., Agid Y. Striatal dopamine deficiency in Parkinson's disease role of aging . Ann. Neurol. 26:(4):1989;551-557.
40. Standaert D.G., Testa C.M., Young A.B., Penney J.B. Jr. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J. Comp. Neurol. 343:(1):1994;1-16.
41. Steece-Collier K., Chambers L.K., Jaw-Tsai S.S., Menniti F.S., Greenamyre J.T. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors. Exp. Neurol. 163:(1):2000;239-243 doi:10.1006/exnr.2000.7374.
42. Sutoo D., Akiyama K. Effect of magnesium on calcium-dependent brain function that prolongs ethanol-induced sleeping time in mice. Neurosci. Lett. 294:(1):2000;5-8.
43. Suzuki T., Okumura-Noji K. NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. Biochem. Biophys. Res. Commun. 216:(2):1995;585-588 doi:10.1006/bbrc.1995.2662.
44. Verhagen Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50:(5):1998;1323-1326.
45. Yamakura T., Mori H., Masaki H., Shimoji K., Mishina M. Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. NeuroReport. 4:(6):1993;687-690.